Stock KLBF PT KALBE FARMA TBK.
Add to a list
To use this feature you must be a member
Log inSign up

Financials PT Kalbe Farma Tbk.

Equities

KLBF

ID1000125107

Pharmaceuticals

End-of-day quote INDONESIA S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
1,405 IDR -1.75% Intraday chart for PT Kalbe Farma Tbk. +0.36% -12.73%
Apr. 01 PT Kalbe Farma Tbk. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Feb. 20 Nomura Adjusts Kalbe Farma’s Price Target to IDR1,850 From IDR2,500, Keeps at Buy MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 75,937,698 69,371,962 75,699,810 96,674,291 74,471,583 64,989,176 - -
Enterprise Value (EV) 2 73,518 65,231 69,972 93,892 74,472 61,678 59,653 59,311
P/E ratio 30.3 x 25.4 x 24.6 x 28.7 x 26.9 x 20.4 x 18.3 x 16.3 x
Yield 1.6% 1.76% 1.73% - - 2.26% 2.42% 2.84%
Capitalization / Revenue 3.35 x 3 x 2.88 x 3.34 x 2.45 x 2 x 1.85 x 1.77 x
EV / Revenue 3.25 x 2.82 x 2.67 x 3.25 x 2.45 x 1.9 x 1.7 x 1.62 x
EV / EBITDA 19.5 x 15.8 x 15 x 19 x 17.1 x 12.8 x 11.1 x 10.3 x
EV / FCF 95.5 x 19.8 x 30.1 x 166 x - 15.4 x 26.6 x 21 x
FCF Yield 1.05% 5.05% 3.32% 0.6% - 6.5% 3.76% 4.76%
Price to Book 4.78 x 3.99 x 3.87 x 4.74 x - 2.8 x 2.59 x 2.44 x
Nbr of stocks (in thousands) 46,875,122 46,872,947 46,872,947 46,255,641 46,255,641 46,255,641 - -
Reference price 3 1,620 1,480 1,615 2,090 1,610 1,405 1,405 1,405
Announcement Date 2/27/20 4/7/21 2/22/22 3/28/23 4/1/24 - - -
1IDR in Million2IDR in Billions3IDR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 22,636 23,113 26,255 28,934 30,449 32,452 35,129 36,656
EBITDA 1 3,771 4,137 4,649 4,946 4,360 4,803 5,392 5,779
EBIT 1 3,300 3,555 4,021 4,231 3,694 4,077 4,593 5,013
Operating Margin 14.58% 15.38% 15.32% 14.62% 12.13% 12.56% 13.08% 13.68%
Earnings before Tax (EBT) 1 3,348 3,628 4,073 4,459 3,606 4,419 4,661 4,797
Net income 1 2,499 2,733 3,074 3,382 2,767 3,439 3,572 3,726
Net margin 11.04% 11.83% 11.71% 11.69% 9.09% 10.6% 10.17% 10.16%
EPS 2 53.48 58.31 65.60 72.71 59.81 68.77 76.77 85.98
Free Cash Flow 3 769,646 3,294,552 2,322,036 566,431 - 4,012,000 2,241,500 2,823,000
FCF margin 3,400.1% 14,254.32% 8,844.17% 1,957.7% - 12,363% 6,380.82% 7,701.24%
FCF Conversion (EBITDA) 20,412.02% 79,640.87% 49,942.71% 11,452.5% - 83,535.72% 41,569.2% 48,852.63%
FCF Conversion (Net income) 30,798.15% 120,535.64% 75,537.95% 16,747.36% - 116,671.99% 62,759.02% 75,764.9%
Dividend per Share 2 26.00 26.00 28.00 - - 31.76 34.02 39.89
Announcement Date 2/27/20 4/7/21 2/22/22 3/28/23 4/1/24 - - -
1IDR in Billions2IDR3IDR in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 6,728 - - - - - - 7,310 - 7,888 - - - -
EBITDA - - - - - - - 1,051 - - - - - -
EBIT 1,203 - - - - - - 877.6 - 979 - - - -
Operating Margin 17.87% - - - - - - 12.01% - 12.41% - - - -
Earnings before Tax (EBT) - - - - - - - 843.4 - 955.2 - - - -
Net income 790.4 786.3 - 802.1 848.6 896.7 855.7 673.3 535.9 701.8 - - - -
Net margin 11.75% - - - - - - 9.21% - 8.9% - - - -
EPS 16.87 16.79 - 17.26 18.32 19.28 18.40 14.47 11.52 15.42 - - - -
Dividend per Share 1 - - - 35.00 - - - 38.00 - - - 29.49 - -
Announcement Date 10/25/21 2/22/22 4/28/22 7/29/22 10/31/22 3/28/23 4/28/23 8/7/23 10/31/23 4/1/24 - - - -
1IDR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 2,419 4,141 5,728 2,782 - 3,311 5,337 5,678
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 2 769,646 3,294,552 2,322,036 566,431 - 4,012,000 2,241,500 2,823,000
ROE (net income / shareholders' equity) 16.4% 16.4% 17.2% 16.9% - 14.3% 14.6% 15.1%
ROA (Net income/ Total Assets) 13.1% 12.8% 13.2% 12.8% - 11.8% 11.2% 11.2%
Assets 1 19,146 21,414 23,288 26,454 - 29,224 31,946 33,268
Book Value Per Share 3 339.0 371.0 418.0 441.0 - 501.0 542.0 577.0
Cash Flow per Share 3 53.40 90.10 60.30 27.30 - 102.0 89.70 94.00
Capex 1 1,733 927 457 705 - 1,111 988 966
Capex / Sales 7.66% 4.01% 1.74% 2.44% - 3.42% 2.81% 2.64%
Announcement Date 2/27/20 4/7/21 2/22/22 3/28/23 4/1/24 - - -
1IDR in Billions2IDR in Million3IDR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for PT Kalbe Farma Tbk.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
1,405 IDR
Average target price
1,773 IDR
Spread / Average Target
+26.22%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
PT KALBE FARMA TBK. Stock PT Kalbe Farma Tbk.
-12.73% 4.01B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. KLBF Stock
  4. Financials PT Kalbe Farma Tbk.